Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates

HAN Chun; WU Lintao; HU Xiaoqin; SUN Long; HUANG Zhangjian; ZHANG Yihua

doi:10.11665/j.issn.1000-5048.20180107

Journal of China Pharmaceutical University > 2018 > 49(1): 48-55. > DOI: 10.11665/j.issn.1000-5048.20180107

HAN Chun, WU Lintao, HU Xiaoqin, SUN Long, HUANG Zhangjian, ZHANG Yihua. Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates[J]. Journal of China Pharmaceutical University, 2018, 49(1): 48-55. DOI: 10.11665/j.issn.1000-5048.20180107

Citation:

PDF (1180 KB)

Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates

More Information

Graphical Abstract

Abstract

Abstract

To search for potent drugs against non-small-cell lung cancer(NSCLC), a series of hybrids( 9a - 9e , 10a - 10e and 11a - 11e) from anilinopyrimidines and diazeniumdiolates were designed and synthesized. The MTT assay was employed to evaluate their antiproliferative activity against H1975 cells harboring epithelial growth factor receptor(EGFR)L858R/T790M mutation. The results showed that compounds 9a - 9e displayed remarkable inhibitory activity on H1975 cells. Among these compounds, the most potent was compound 9b (IC₅₀=0. 65 μmol/L), which was superior to the positive control gefitinib. Additionally, molecular docking study indicated that 9b could bind with EGFR T790M by forming hydrogen bond, electrostatic interactions, et al, suggesting that compound 9b may be a potential anti-NSCLC agent for further investigation.
- anilinopyrimidines,
- diazeniumdiolates,
- epithelial growth factor receptor,
- gefitinib,
- synthesis,
- non-small cell lung cancer,
- antitumor activity

FullText(HTML)

References (16)

References

[1]	Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2]	Herbst RS,Heymach JV,Lippman SM.Lung cancer[J].N Engl J Med,2008,359(13):1367-1380.
[3]	Johnson BE,Janne PA.Epidermal growth factor receptor mutations in patients with non-small cell lung cancer[J].Cancer Res,2005,65(17):7525-7529.
[4]	Govindan R.A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer[J].Clin Lung Cancer,2010,11(1):8-12.
[5]	Finlay MR,Anderton M,Ashton S,et al.Discovery of a potent and selective EGFR inhibitor(AZD9291)of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor[J].J Med Chem,2014,57(20):8249-8267.
[6]	Walter AO,Sjin RT,Haringsma HJ,et al.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC[J].Cancer Discov,2013,3(12):1404-1415.
[7]	Zhou W,Ercan D,Chen L,et al.Novel mutant-selective EGFR kinase inhibitors against EGFR T790M[J].Nature,2009,462(7276):1070-1074.
[8]	Basudhar D,Ridnour LA,Cheng R,et al.Biological signaling by small inorganic molecules[J].Coord Chem Rev,2016,306(Pt 2):708-723.
[9]	Huang Z,Fu J,Zhang Y.Nitric oxide donor-based cancer therapy:advances and prospects[J].J Med Chem,2017,60(18):7617-7635.
[10]	Cheng H,Wang L,Mollica M,et al.Nitric oxide in cancer metastasis[J].Cancer Lett,2014,353(1):1-7.
[11]	Han C,Huang Z,Zheng C,et al.Novel hybrids of(phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer[J].J Med Chem,2013,56(11):4738-4748.
[12]	Han C,Huang Z,Zheng C,et al.Nitric oxide donating anilinopyrimidines:synthesis and biological evaluation as EGFR inhibitors[J].Eur J Med Chem,2013,66:82-90.
[13]	Han C,Wan L,Ji H,et al.Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growthfactor receptor inhibitors[J].Eur J Med Chem,2014,77:75-83.
[14]	Huang Z,Kaur J,Bhardwaj A,et al.O²-sulfonylethyl protected isopropylamine diazen-1-ium-1,2-diolates as nitroxyl(HNO)donors:synthesis,beta-elimination fragmentation,HNO release,positive inotropic properties,and blood pressure lowering studies[J].J Med Chem,2012,55(22):10262-10271.
[15]	Hong SY,Saavedra JE,Keefer LK,et al.Improved synthesis of V-PYRRO/NO,a liverselective nitric oxide prodrug,and analogues[J].Tetrahedron Lett,2009,50(18):2069-2071.
[16]	Hamann JN,Rolff M,Tuczek F.Monooxygenation of an appended phenol in a model system of tyrosinase:implications on the enzymatic reaction mechanism[J].Dalton Trans,2015,44(7):3251-3258.

Cited By

Get Citation

PDF

XML

Article views (805) PDF downloads (1096)

Turn off MathJax

Article Contents

Abstract

References

Design, synthesis and anti-NSCLC activity of hybrids of anilinopyrimidines and diazeniumdiolates

Abstract

References

Catalog

Export File

Citation

Format

Content